Find a Trial

Trial Summary


Protocol No.CTO-INCB-50465-304
StatusOPEN TO ACCRUAL
Principal InvestigatorSayar, Hamid
ScopeNational
PhasePhase III
Age GroupAdult
TitleA Randomized, Double-Blind, Placebo-Controlled Study of the PI3Kδ Inhibitor Parsaclisib Plus Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib.
Applicable Disease SitesLeukemia, other
Participating InstitutionsIU Health Central Indiana Cancer Centers
    Indiana University (IU)
      Treatment TypeTreatment
      ContactPhone: (317) 278-5632
      Email: iutrials@iu.edu